With the New Year, new guidelines! Our COVID-19 therapeutic working group has revised our COVID-19 management guidelines. Of note, empiric antibiotics are strongly DISCOURAGED for mild and moderate disease. Investigational or off-label therapies should NOT be given outside of clinical trials (several ongoing clinical trials at the MUHC); Criteria are proposed for potential identification of hyperimmune response, with recommendations to consult ID for severe cases.
The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus aureus bacteremia. The diagnostic and antibiotic choice are di
ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator
The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar